Body mass index and chemotherapy completion among patients with newly diagnosed ovarian cancer.

ABSTRACT:

Background

Several ovarian cancer studies have suggested that a body mass index (BMI) of 30 or higher is associated with lower compliance with National Comprehensive Cancer Network-recommended chemotherapy but primarily involved treatment before 2012, when dose capping was recommended for patients with higher body surface areas. Updated analyses in the contemporary treatment era are warranted.

Methods

In a retrospective cohort of patients with newly diagnosed ovarian cancer receiving curative-intent carboplatin plus paclitaxel in the Yale-Smilow Cancer Network (2012-2022), we evaluated BMI at diagnosis in relation to relative dose intensity (RDI)-the ratio of completed chemotherapy dose intensity to the National Comprehensive Cancer Network-recommended dose intensity-which r

SUBMITTER: Cao A 

PROVIDER: S-EPMC12854082 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature